Skip Navigation


JAC Advance Access originally published online on November 16, 2004
Journal of Antimicrobial Chemotherapy 2004 54(6):1144-1147; doi:10.1093/jac/dkh486
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/6/1144    most recent
dkh486v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kim, J.-Y.
Right arrow Articles by Lee, K.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, J.-Y.
Right arrow Articles by Lee, K.-Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC vol.54 no.6 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved

Nosocomial outbreak by Proteus mirabilis producing extended-spectrum ß-lactamase VEB-1 in a Korean university hospital

Ja-Young Kim1, Yeon-Joon Park1,*, Sang-Il Kim2, Moon Won Kang2, Seung-Ok Lee1 and Kyo-Young Lee1

Departments of 1 Clinical Pathology and 2 Internal Medicine, College of Medicine, The Catholic University of Korea, Kangnam St Mary's Hospital, 505 Banpo-dong, Seocho-ku, Seoul, 137-701, Korea

* Corresponding author. Tel: +82-2-590-1604; Fax: +82-2-592-4190; Email: yjpk{at}catholic.ac.kr

Objectives: To examine the molecular mechanisms involved in the ß-lactam resistance of multidrug-resistant Proteus mirabilis isolates that showed an unusual synergy between imipenem and ceftazidime in a Korean hospital.

Methods: Over an 11 month period, a total of 12 P. mirabilis isolates showing resistance to ampicillin, gentamicin, ceftazidime, cefotaxime, cefuroxime, cefalothin, cefepime, piperacillin, trimethoprim/sulfamethoxazole and ciprofloxacin, were recovered from the sputum and urine specimens of nine patients who were hospitalized in the neurosurgery ward. The extended-spectrum ß-lactamases were screened with a double disc synergy test using ceftazidime, cefotaxime, aztreonam, cefepime and clavulanate. The ESBL types were determined by PCR using specific primers for blaTEM-1, blaSHV-1, blaCTX-M-1, blaCTX-M-2, blaCTX-M-8, blaCTX-M-9, blaPER-1, blaGES-1, blaVEB-1, blaOXA-10 and blaOXA-13 followed by sequencing. All the isolates underwent molecular typing by PFGE. The transferability was examined by conjugation.

Results and conclusions: All the isolates showed a marked synergy between the extended-spectrum cephalosporins and clavulanate together with an unusual synergy between cefoxitin and the cephalosporins (cefalothin, cefuroxime, ceftazidime, cefotaxime) and between imipenem, and ceftazidime and cefotaxime. Isoelectric focusing of the crude bacterial extracts showed a ß-lactamase band with a pI value of 5.4, which was inhibited by clavulanate. PCR and sequencing identified the gene to be blaVEB-1. In addition, the aadB gene was detected, conferring aminoglycoside resistance. The resistance was not transferred by conjugation. The outbreak was of a clonal origin as shown by PFGE demonstrating an identical banding pattern. This is the first report of VEB-1-producing Enterobacteriaceae in Korea.

Keywords: P. mirabilis , ESBLs , ß-lactam resistance , multidrug-resistant


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
Z. Zong, S. R. Partridge, and J. R. Iredell
A blaVEB-1 Variant, blaVEB-6, Associated with Repeated Elements in a Complex Genetic Structure
Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1693 - 1697.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
L. M. Aragon, B. Mirelis, E. Miro, C. Mata, L. Gomez, A. Rivera, P. Coll, and F. Navarro
Increase in {beta}-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type {beta}-lactamases
J. Antimicrob. Chemother., May 1, 2008; 61(5): 1029 - 1032.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. Naas, D. Aubert, T. Lambert, and P. Nordmann
Complex Genetic Structures with Repeated Elements, a sul-Type Class 1 Integron, and the blaVEB Extended-Spectrum {beta}-Lactamase Gene.
Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1745 - 1752.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. Aubert, T. Naas, M.-F. Lartigue, and P. Nordmann
Novel Genetic Structure Associated with an Extended-Spectrum {beta}-Lactamase blaVEB Gene in a Providencia stuartii Clinical Isolate from Algeria
Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3590 - 3592.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Endimiani, F. Luzzaro, G. Brigante, M. Perilli, G. Lombardi, G. Amicosante, G. M. Rossolini, and A. Toniolo
Proteus mirabilis Bloodstream Infections: Risk Factors and Treatment Outcome Related to the Expression of Extended-Spectrum {beta}-Lactamases
Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2598 - 2605.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.